Kabardine transdermal patch was developed by Novartis in Switzerland and was initially approved by the US FDA in 2000, becoming the world's first transdermal patch for the treatment of Alzheimer's disease.

1、 Drug name

1. Common name: Rivastigmine

2. Product Name: Exelon ® Patch (Aisneng transdermal patch)

2、 Indications

1. Treatment of mild to moderate Alzheimer's dementia

2. Treating mild to moderate dementia associated with Parkinson's disease

3、 Specifications and characteristics

1. 4.6mg/24-hour specification: 5cm ² patch, containing 9mg of Kabardine

2. Appearance: Opaque plastic patch, four layer structure (backing layer, drug matrix layer, adhesive layer, release liner)

4、 Main components

1. Active ingredient: Kabardine ((S) -3- [1- (dimethylamino) ethyl] phenylethyl methyl carbamate)

2. Accessories: acrylic copolymer, silicone adhesive, silicone oil, vitamin E, etc

5、 Usage and dosage

1. Initial dose: 4.6mg/24-hour patch, once daily

2. Maintenance dose: If well tolerated after 4 weeks, increase to 9.5mg/24-hour patch (recommended effective dose)

3. Maximum dose: 9.5mg/24 hours, higher doses have no additional benefits and increase adverse reactions

4. Usage: Apply to clean and dry skin on the back, upper arms, or chest, and change the area daily

6、 Dose adjustment

1. Low weight patients (<50kg): The dosage should be carefully adjusted and may need to be maintained at 4.6mg/24 hours

2. Treatment interruption>several days: need to restart from the lowest dose

3. Oral preparation conversion:

Original daily dose<6mg orally: switch directly to 4.6mg/24-hour patch

Original daily dose 6-12mg oral: directly switch to 9.5mg/24-hour patch

7、 Medication precautions

1. Medication time: No need to consider before and after meals

2. Leakage handling: Immediately replace with new patches and replace them the next day according to the original plan

3. Vomiting treatment: restart from low dose after pausing treatment for several days

4. Skin care: avoid using cream/talcum powder recently, and do not reuse the same part within 14 days

5. Special Reminder:

Fold and dispose of after use to prevent children from coming into contact with residual drugs

Bathing/swimming does not affect the patch, but long-term exposure to high temperatures should be avoided

8、 Medication for special populations

1. Pregnant women: Use only when the benefits outweigh the risks (pregnancy grade B)

2. Breastfeeding period: Prohibited (drugs may be secreted through breast milk)

3. Children: No safety and efficacy data available

4. Liver dysfunction: No need to adjust dosage, but individualized titration is required

5. Renal insufficiency: No need to adjust dosage

6. Elderly patients: Age does not affect pharmacokinetics

9、 Adverse reactions

1. Common (≥ 5%): Nausea (7%), vomiting (6%), diarrhea (6%)

2. Skin reaction: redness/itching at the application site (mostly mild)

3. Other significant adverse reactions:

Weight loss (≥ 7% baseline weight: 8%)

Dizziness, headache, decreased appetite

4. Rare but severe: gastrointestinal bleeding, epileptic seizures, extrapyramidal symptoms

10、 Contraindications

Known to be allergic to carbapenem, other carbamate derivatives, or patch ingredients

Lactating women

11、 Drug interactions

1. Prohibition of combination use: Other cholinergic drugs (including oral Kabardine preparations)

2. Use with caution:

Succinic cholinergic muscle relaxants (may enhance effect during anesthesia)

Anticholinergic drugs (possibly antagonistic to each other)

12、 Storage method

1. Room temperature storage (15-30 ° C)

2. Keep sealed until use

3. Discarded patches need to be folded and safely disposed of

Rivastigmineinformation